Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting
Nano Today, ISSN: 1748-0132, Vol: 43, Page: 101403
2022
- 34Citations
- 63Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations34
- Citation Indexes33
- 33
- CrossRef13
- Policy Citations1
- 1
- Captures63
- Readers63
- 63
- Mentions1
- News Mentions1
- 1
Most Recent News
Latest Developments in mRNA Technology for Vaccines: Moving Beyond COVID-19
Introduction The COVID-19 pandemic has led to expedited approvals for the use of messenger ribonucleic acid (mRNA) technology in the development of vaccines. More specifically,
Article Description
BioNTech/Pfizer’s Comirnaty and Moderna’s SpikeVax vaccines consist in mRNA encapsulated in lipid nanoparticles (LNPs). The modularity of the delivery platform and the manufacturing possibilities provided by microfluidics let them look like an instant success, but they are the product of decades of intense research. There is a multitude of considerations to be made when designing an optimal mRNA-LNPs vaccine. Herein, we provide a brief overview of what is presently known and what still requires investigation to optimize mRNA LNPs vaccines. Lastly, we give our perspective on the engineering of 3D bioprinted validation systems that will allow faster, cheaper, and more predictive vaccine testing in the future compared with animal models.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1748013222000305; http://dx.doi.org/10.1016/j.nantod.2022.101403; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85123777196&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35079274; https://linkinghub.elsevier.com/retrieve/pii/S1748013222000305; https://dx.doi.org/10.1016/j.nantod.2022.101403
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know